, but compared to the general toxicity, some parameters indicating immunotoxic effects were also affected at lower doses (10 and 30 mg/kg). In conclusion, immunotoxicity of B[a]p can be detected using parameters of the immune system such as described in the recently updated OECD 407 guideline. In the present study thymus weight changed and spleen B-cell populations were affected at a dose of 10 mg/kg, a level where no overt general toxicity was noted.
The recently updated OECD guideline 407 (OECD, 1995) , is aimed at establishing the toxicological profile of the test compound. Recently, a limited set of non-antigen specific general immune assays have been added to the routine histopathological evaluation of short term toxicity studies in order to cover potential effects on the immune system. It is often debated whether such protocols are sufficiently sensitive to establish potential immunotoxicity.
In view of the immunosurveillance against tumors, immunosuppression might play a role in the carcinogenesis of benzoa-pyrene (B [a] p), in addition to a direct genotoxic activity of B [a] p. Therefore, in conjunction with a carcinogenicity study, a tiered approach for immunotoxicity testing was performed (Van Loveren and Vos, 1996; Van Loveren, 1987, 1994) . The experiment was conducted largely in agreement with the recently updated OECD guideline 407.
A sub-acute oral toxicity study in rats that includes parameters of the immune system has not been carried out so far. Most in vivo studies for the detection of B [a] P immunotoxicity have used parenteral (ip or sc) administration in mice. Decreased spleen, thymic, and bone marrow cellularity were noted (Deane et al., 1983; Holladay and Smith, 1995) . In-utero exposure resulted in severe thymic atrophy and thymic hypocellularity (Holladay and Smith, 1994) , and disturbed the Tcell subpopulations present in liver, spleen, and thymus (Lummus and Henningsen, 1995) . For humoral immune responses, decreased IgM levels were measured in both mice and rats after SRBC immunization of B [a] p-treated animals (Temple et al., 1993) .
Spleen polyclonal responses (3H-TdR incorporation and IgM synthesis) in mice were suppressed after ip administration of 200 mg/kg B [a] p (Ginsberg et al., 1989) and the immunosuppression was ascribed to direct cytotoxicity of B [a] p. In vivo exposure of 40 mg/kg for 14 days resulted in severe (98%) suppression of in vitro T-cell-dependent antibody responses of spleen cells (Blanton et al. 1986 ). Similar to in-vitro exposure, in-vivo exposure to B [a] p (single ip dose of 180 mg/kg) resulted in a decrease of virally-induced interferon production (Griffin et al. 1986 ). In addition, the IL2 production of spleen cells was reduced after sc treatment (Lyte et al. 1987; Myers et al. 1988) . B [a] p treatment of C57 and C3H mice suppressed cytotoxic activity of antigen sensitized splenic lymphocytes (SL) and peritoneal exudate lymphocytes (PEL) when compared to oil-injected controls (Wojdani et al. 1984) .
In addition, immunological reactivity to the PAHs 7,12-dimethylbenz [a] anthracene and B [a] p indicates that the immune system, at least potentially, may modify the disposition of these carcinogens (Anderson et al. 1995; Klemme et al. 1987) . Moreover, antibodies against B [a] p DNA adducts may be formed (Harris et al. 1985; Haugen et al. 1986; Pulera et al. 1997) .
The study presented herein was aimed at establishing whether immunotoxicity of B [a] P could be detected using parameters of the immune system such as described in the recently updated OECD 407 guideline.
MATERIALS AND METHODS
Animals. Forty animals randomly allocated to the control and 4 treatment groups, each consisting of 8 male Riv:Tox Wistar SPF rats, 6 weeks-of-age, were used. The animals were housed under SPF conditions in Macrolon type III cages, 2 per cage, and were fed SSP Tox chow (Hope Farms, Woerden, The Netherlands) and water ad libitum. Low-fat to fat-free chow was prepared as the benzo [a] pyrene was dissolved in soybean oil. A 12-h light/dark cycle was employed and the animal room underwent 15 fresh air changes per h. All other husbandry conditions were maintained according to all applicable provisions of the following national laws: Experiments on Animals Decree, and Experiments on Animals Act.
Experimental design. Benzo [a] pyrene (B [a] p) CAS-reg no 50 -32-8, MW 252.3, batch number 24022, purity 98.6 Ϯ 0.4 % was obtained from Serva, Heidelberg, Germany. The B [a] p was dissolved in soybean oil, and administered by gavage, 5 days a week, Mondays to Fridays, at a dosage of 0, 3, 10, 30, or 90 mg/kg body weight. After 35 days exposure to B [a] p, blood was obtained by orbital puncture under ether anesthesia and the animals were then necropsied.
Pathology. The animals were killed by exsanguination from the abdominal aorta during ether anaesthesia. After general gross inspection, the following organs were examined and sampled: adrenals, brain, bone marrow, colon (ascending and descending parts), caecum, jejunum, heart, kidney, liver, lung, lymph nodes (mandibular, mesenteric and popliteal), esophagus, pituitary, spleen, stomach, testis, and thymus. Organ weights were determined except for bone marrow, pituitary, and gastrointestinal tract.
All tissue samples were fixed in 4% neutral buffered formaldehyde and routinely processed (H and E stain) for histopathology. Morphometrical analysis of the thymus was done using the IBAS 2000 image analysis system (Kontron, Munich). The relative cortex surface area was determined, and cortical and medulla weights were calculated. Immunohistochemistry of the thymus was performed for detection of cellular proliferation with anti-proliferating cell nuclear antigen (PCNA) antibody (DAKO A/S, Glostrup, Denmark). Binding of the monoclonal antibody was detected by additional incubation with peroxidase-labeled rabbit-anti mouse and swine-anti-rabbit antibodies (DAKO A/S).
Hematology. The blood was collected in EDTA-coated tubes. Hematological parameters included white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin (Hb), hematocrit (Ht), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and platelet count (PLT ). All hematology parameters in the blood samples were determined in a Sysmex E4000 hematology analyzer (Toa Medical Electronics Co., Ltd, Kobe, Japan). In addition, blood smears were prepared for visual evaluation, depending on the results obtained with the hematology analyzer.
Bone marrow. Cells were collected by flushing 4 ml Impuls Cytometer Fluid through the left femur. The concentration of nucleated cells was determined in a Coulter Counter.
Determination of immune parameters.
Half of the spleen was weighed and collected in tissue culture medium and spleen cells were isolated. Relative spleen cell distribution was determined by FACS (fluorescence-activated cell sorter) analysis. Spontaneous cytotoxicity of spleen cell populations was determined in a natural killer (NK) cell assay (de Jong et al. 1980) . Serum was collected for determinations of immunoglobulin (IgG, IgM, IgE, and IgA) levels (Van Loveren et al. 1988; Vos et al. 1982) . The immunological assays are described in detail elsewhere (Vos and Van Loveren, 1987) .
Statistical analysis. Statistical analysis between treated and control animals was performed with a one way ANOVA for dose response effects and differences between groups. For hematological data critical values for testing outliers were determined according to Dixon Sokal and Rohlf, 1981) . Histopathology scores were evaluated with the Fisher's exact test.
RESULTS

General Toxicity
From week 2 onwards, a significant (p Ͻ 0.001) growth retardation was observed in the 90-mg/kg dose group. For the other dose groups in general, there was a non-significant reduction in body weights; the only significant reduction (p Ͻ 0.05) was for the 3-mg/kg dose group at week 5 of exposure (data not shown). Brain weight was decreased in the 90-mg/kg group; heart weight was decreased in the 3-mg/kg and 90-mg/kg group; and kidney weight was decreased in the 3-mg/kg, 30-mg/kg and 90-mg/kg-treated group. In contrast, for the liver, an increase in weight was observed which was statistically significant (p Ͻ 0.01) at the highest dose (90 mg/kg) administered (Table 1) .
At routine histopathology, and only in the liver and forestomach, we observed treatment-related lesions . In the forestomach, basal cell hyperplasia (p Ͻ 0.05, Fisher's exact test) occurred locally with a minor increase of basal cells characterized by an irregular arrangement of the cells, with rodshaped, atypical polymorphic nuclei, and/or cells with a minor vacuolation. An increase was noted for the 2 highest B[a]P dose groups (30 and 90 mg/kg). In the liver, oval cell proliferation occurred in the highest dose benzo [a] pyrene-treated animals (p Ͻ 0.01, Fisher's exact test). Although clear cell foci were also only noted in B [a] p-treated animals, the increase in occurrence was not significant (p ϭ 0.0769, Fisher's exact test), and it was present only in the highest-dose group. Inflammatory cell foci in the liver, which are present as back ground histopathology in our rat colony, showed an increasein-severity score with increasing B [a] p dosage (data not shown). In addition, necrotic liver parenchymal cells were observed in the larger inflammatory cell foci.
Toxicity in Lymphoid Organs
Thymus weight had a dose-related decrease at the 10, 30, and 90 mg/kg doses. Also lymph nodes showed a decrease at the 90 mg/kg dose. (Table 1 ). In the thymus, indications for cortical atrophy were noted in the highest-dose group. Quantitative morphometric analysis of the thymus was performed for all treatment groups. The relative cortex surface area of the thymus was decreased by a statistically significant amount for the highest dose (90 mg/kg body weight, p Ͻ 0.01) investigated (Table 2 ). Based on thymus weight cortical and medullary weight were calculated. A reduction in thymic cortex weight was present at 10, 30, and 90 mg/kg B [a] p treatment, while the thymic medullar weight was reduced at the 90-mg/kg dose. Additional immunoperoxidase staining of the thymus for PCNA did not reveal a difference in proliferating activity between B[a]p-treated and control animals (data not shown).
The absolute number of cells harvested per spleen was significantly decreased in the highest dose group (90 mg/kg) ( Table 3 ). In addition, the relative cellular distribution of spleen cells, determined by FACS analysis, showed a doserelated decrease for the relative amount of B cells in the spleen in the 10-mg/kg, 30-mg/kg, and 90-mg/kg dose groups (Table  3 ). The total number of B cells in the spleen was decreased only for the highest-dose group of 90 mg/kg (p Ͻ 0.001). At the 3-mg/kg dose level, an increase in the number of total T cells and T helper cells was observed (p Ͻ 0.05).
In the bone marrow, a decrease was observed in cell number in the highest-dose group (90 mg/kg) ( Table 3 ). The bone marrow toxicity is reflected by a decrease in the amount of both red and white blood cells (see below).
Hematology
Examination of whole blood samples revealed a dose related decrease for the red blood cell count (RBC), hemoglobin (Hb), and hematocrit (Ht) in 10 mg/kg, 30 mg/kg and 90 mg/kg dose groups (Table 4 ). The mean cell volume (MCV), and the mean corpuscular hemoglobin concentration (MCHC) were minimally but significantly increased (MCV, p Ͻ 0.05) or decreased (MCHC, p Ͻ 0.01), respectively, at the 90 mg/kg dosages. A change in red blood cell distribution is indicated by the significant increases of the RDW and Q-index values (90 mg/kg dose group). The results indicate a dose related toxicity for red blood cells and/or red blood cell precursors in the bone marrow. The decrease in white blood cell count (WBC) in the 90 mg/kg treatment group is due to a decrease in the number of lymphocytes (approximately 50%) and eosinophils (approximately 90%), while the absolute number of neutrophils and monocytes remained at control levels (Table 4) . (Table 5) .
Natural Killer Cell Activity
The highest dose of benzo [a] pyrene treatment resulted in a significant (p Ͻ 0.001) decrease of natural-killer (NK) cell activity in the spleen; the E:T ratio was 100, control 100 Ϯ 42.7% and B [a] p 40.9 Ϯ 28.4% (mean Ϯ sd expressed as a percentage of non-treated controls).
DISCUSSION
In this study, both general and immunotoxic effects of B [a] p were determined after 35 days oral (gavage) exposure in male 23 Ϯ 7 2 6 Ϯ 5 2 0 Ϯ 5 2 0 Ϯ 5 9 Ϯ 3*** T cells 23 Ϯ 6 3 4 Ϯ 10* 24 Ϯ 7 2 3 Ϯ 3 1 8 Ϯ 5 Th cells 13 Ϯ 4 1 8 Ϯ 3* 15 Ϯ 5 1 4 Ϯ 3 1 1 Ϯ 4 Ts cells 14 Ϯ 4 1 8 Ϯ 6 1 7 Ϯ 11 12 Ϯ 2 1 1 Ϯ 4 Bone marrow cells (G/l) 31 Ϯ 7 3 6 Ϯ 5 3 1 Ϯ 8 2 7 Ϯ 8 1 9 Ϯ 4** Spleen (relative distribution in %) B cells (MARK-I) 39 Ϯ 4 3 6 Ϯ 2 3 4 Ϯ 3** 32 Ϯ 4** 23 Ϯ 4*** T cells 40 Ϯ 9 4 8 Ϯ 12 40 Ϯ 9 3 6 Ϯ 2 4 4 Ϯ 6 Th cells 23 Ϯ 7 2 6 Ϯ 7 2 4 Ϯ 5 2 2 Ϯ 4 2 6 Ϯ 4 Ts cells 24 Ϯ 5 2 6 Ϯ 6 2 4 Ϯ 7 1 9 Ϯ 2 2 7 Ϯ 5
Note. Benzo [a] pyrene was administered by oral gavage 5 days a week for 5 consecutive weeks. a Mean Ϯ sd (n ϭ 7-8). Significant differences from control group (0 mg/kg): *p Ͻ 0.05, **p Ͻ 0.01, and ***p Ͻ 0.001, one way ANOVA. rats, carried out in accord with the recently updated OECD 407 guidelines. B [a] p treatment-related general toxicity was mainly observed in the highest dose (90 mg/kg) administered. By 2 weeks of oral exposure, growth retardation had occurred in the animals. General toxic effects included a decrease in body weight, and in weight of brain, heart and kidney, while there was a weight increase in the liver. In addition, histopathological lesions were observed in the forestomach (increase in basal cell hyperplasia), and in the liver (clear cell foci and oval cell hyperplasia). In all animals, inflammatory cell foci were present in the liver. A limited dose-related shift in severity of the foci was seen. No clinical signs were noted that could be associated with these inflammatory lesions. Yet, the lesions are likely accompanied by production of inflammatory interleukins, which have been shown to influence detoxification enzymes (Langouet et al. 1995) . The sensitivity of the animals used in this study may therefore have been influenced by this condition.
With regard to the immune parameters, a dose-related effect, starting at a dose of 10 mg/kg, was observed for decreases in both thymus weight and in the relative B-cell distribution in the spleen. At a dose of 3 mg/kg, increased T-cell numbers was observed, although no dose-response relationship, and it can therefore be argued whether this effect is biologically significant, especially in light of the fact that the number of circulating WBC (lymphocytes and eosinophilic granulocytes) was decreased. Other high dose-related effects were a decrease in lymph node weight and a reduction in the amount of cells present in the spleen and bone marrow. In addition, a decrease in serum IgM and IgA was seen.
Thymic weight showed a dose-response effect, with the dose of 10 mg/kg already inducing a significant reduction. Also in the National Toxicology Program (NTP), thymic weight reduction was a first indicator for immunotoxicity of B [a] p in mice (Luster et al. 1992) . The atrophy in the thymic cortex was not due to a marked decrease in cellular proliferation, as shown by PCNA staining. An absolute decrease in the calculated weight of the thymic cortex was found at dose levels of 10, 30, and 90 mg/kg. In the highest dose investigated (90 mg/kg) B [a] p exposure also resulted in a decrease of the calculated thymic medulla weight. Hence, there might be an overall reduction in both differentiating cortical and differentiated medullary thymocytes.
Within the thymus, various cell types and regions show differential effects to toxic agents. Cortical lymphodepletion may be the result of direct thymocyte toxicity such as induced by bis(tri-n-butyltin) oxide, TBTO Raffray and Cohen, 1991; Vos et al. 1984) . In addition, the thymic epithelium can be the target of toxic compounds as was demonstrated for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Cyclosporine A (De Waal et al. 1997) . Like TCDD B [a] p binds to the Ah receptor and Ah receptor antagonists can block B [a] p lymphotoxicity (Davila et al. 1996) . As the Ah receptor is present both on the thymic epithelium and the thymocytes, B [a] p thymotoxicity may be explained by either direct thymocyte cytotoxicity or an indirect mechanism via the thymic epithelium. On the other hand, B [a] p also induced bone marrow toxicity, so a reduced thymic influx of precursors may have contributed to the thymic atrophy. Further studies are needed to elucidate the actual mechanism of B [a] p thymotoxicity.
A decrease in cellularity was observed in the bone marrow, spleen, and in the circulation. For the WBC, the reduction was mainly due to a dramatic decrease (almost 50%) of the circulating lymphocytes. In mice, reduced thymic and bone marrow cellularity also occurred after intraperitoneal administration of B [a] p (Holladay and Smith, 1995) . The decrease in nucleated spleen cell count can perhaps be attributed to a decreased number of B cells; for T cells, only a non-significant decrease was noted. This suggests a possible selective toxicity of B [a] p to B cell precursors in the bone marrow. This idea is supported by results obtained in mice where, in bone marrow cultures, supression of B cell lymphopoiesis was observed (Hardin et al. 1992; Holladay and Smith, 1995) , and in spleens, the amount of B cell was decreased as well (Holladay and Smith, 1995) . In addition, the production of antibodies seems impaired, as indicated by the reductions in IgA and IgM antibody serum levels in our study. Thymus toxicity may also play a role in decreased (T cell-dependent) antibody production.
After B [a] p exposure, contrasting results with regard to Note. Benzo [a] pyrene was administered by oral gavage 5 days a week for 5 consecutive weeks. a Mean Ϯ sd (n ϭ 7-8). Significant differences (ANOVA) from control group are indicated, **p Ͻ 0.01.
tumor burden of B16F10 tumors in the lung were reported; i.e., no effect and an increase in tumor burden (Dean et al. 1986; Luster et al. 1993) . The resistance to B16F10 tumor take is thought to be associated with macrophage and NK cell mediated cytotoxicity. Our results on reduced NK cell acivity are in line with an enhanced B16F10 tumor take observed in mice (Luster et al. 1993) . It is noteworthy that the decreased NK cell activity in our rats does not correlate with the previously observed increase in IL2 and IFN mRNA levels in the spleen (Vandebriel RJ et al. 1998 ).
In conclusion, our data are in line with those reported in the literature, and show that B [a] p exerts immunotoxic activity. In addition, our results show that detection of immunotoxic activity of B [a] p is possible using non-functional immune parameters (i.e., pathology of lymphoid organs) within the context of a regular screening protocol used to determine the toxicological profile of a compound as described in the recently updated OECD guideline 407 (OECD, 1995) . The effects on the immune system were more sensitive as read-out parameters then general toxicity parameters, as indicated by the lower dosages at which marked effects occurred.
